Since its Dec 2021 high: down 73%, while sales grew 138%. 4 more reasons behind ARCT's -1, for Pro members.
Follow ARCT's trial news. Pro members can get an alert when Arcturus Therapeutics Holdings files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 70% over five years while the S&P 500 rose 89%.
Free cash flow went from -$44.6M in fiscal 2020 to -$74.5M in fiscal 2025.
Expected to report Mon Nov 9, after the close
After its last 4 reports it closed +5.0% on average, higher 2 of 4 times.
For Pro members
From Arcturus Therapeutics Holdings’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
About 10 quarters
No shelf registration of its own or at-the-market program on file in the last three years.
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
PoorTrending up, 3 of 14 checks firingWhat the Quality Score means
One per group is shown here.
ARCT is #171 of 306 by Quality Score. The top three are shown with their scores, and more by name.
Expected to report Mon Nov 9, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | +6.4% | +21.9% | +29.3% |
| May 7, 2026After close | After close | -7.6% | +3.6% | -12.0% |
| Mar 3, 2026After close | After close | -5.1% | -4.2% | -3.7% |
| Nov 10, 2025After close | After close | +0.8% | -1.3% | -23.0% |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders, and profits come straight from the SEC. That means Form 4 filings, 13F filings, and XBRL financial data on EDGAR. Where a company's SEC figures leave the Quality Score's sales, share count, or cash flow line empty, the score reads that figure from Massive's statements, and the Score tab says so. A foreign company that files its quarters on Form 6-K has them read from those filings' own statements, every figure as the filing prints it. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch, and Yahoo Finance publish, shown as the headline, the source, and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.